IFI risk in the HSCT cohort according to selected baseline characteristics
Characteristic . | No. . | IFI (%)* . | Days after HSCT . | IR (95% CI)† . | IRR (95% CI)‡ . |
|---|---|---|---|---|---|
| Cohort | 264 | 18 (6.8) | 82 629 | 0.22 (0.13-0.34) | — |
| Sex | |||||
| Female | 107 | 7 (6.5) | 34 346 | 0.20 (0.11-0.41) | — |
| Male | 157 | 11 (7.0) | 48 283 | 0.23 (0.08-0.42) | 1.12 (0.43-2.88) |
| Age, y | |||||
| 18-44 | 135 | 6 (4.4) | 46 861 | 0.13 (0.05-0.28) | — |
| 45-66 | 129 | 12 (9.3) | 35 768 | 0.34 (0.17-0.59) | 2.62 (0.98-6.98) |
| Transplant type | |||||
| Myeloablative | 197 | 8 (4.1) | 64 642 | 0.12 (0.05-0.24) | — |
| Nonmyeloablative | 67 | 10 (14.9) | 17 987 | 0.56 (0.27-1.02) | 4.49 (1.77-11.4) |
| Relationship to donor | |||||
| Related | 143 | 3 (2.1) | 47 156 | 0.06 (0.01-0.19) | — |
| Unrelated | 121 | 15 (12.4) | 35 473 | 0.42 (0.24-0.70) | 6.65 (1.92-23.0) |
| Stem cell source | |||||
| Bone marrow | 164 | 9 (5.5) | 57 717 | 0.16 (0.07-0.30) | — |
| Peripheral blood | 100 | 9 (9) | 24 912 | 0.36 (0.17-0.69) | 2.32 (0.92-5.84) |
| Risk group | |||||
| Low risk | 80 | 3 (3.8) | 30 824 | 0.10 (0.02-0.28) | — |
| High risk | 184 | 15 (8.2) | 51 805 | 0.29 (0.16-0.48) | 2.98 (0.86-10.3) |
| CMV serology of donor/recipient | |||||
| Any seropositive | 137 | 10 (7.3) | 41 868 | 0.24 (0.12-0.44) | 1.30 (0.50-3.42) |
| D-/R- | 118 | 7 (5.9) | 38 105 | 0.18 (0.07-0.38) | — |
| GVHD prophylaxis | |||||
| Methotrexate | 142 | 5 (3.5) | 43 886 | 0.11 (0.04-0.27) | 0.34 (0.12-0.95) |
| No methotrexate | 122 | 13 (10.7) | 38 743 | 0.34 (0.18-0.57) | — |
| Cyclosporine | 121 | 13 (10.7) | 41 729 | 0.31 (0.17-0.53) | 2.55 (0.91-7.15) |
| No cyclosporine | 143 | 5 (3.5) | 40 900 | 0.12 (0.04-0.29) | — |
| Tacrolimus | 107 | 2 (1.9) | 27 257 | 0.07 (0.01-0.27) | 0.25 (0.06-1.10) |
| No tacrolimus | 157 | 16 (10.2) | 55 372 | 0.29 (0.17-0.47) | — |
| Sirolimus | 43 | 1 (2.3) | 11 492 | 0.09 (0.00-0.49) | 0.36 (0.05-2.74) |
| No sirolimus | 221 | 17 (7.7) | 71 137 | 0.24 (0.14-0.38) | — |
| MMF | 13 | 3 (23.1) | 2 719 | 1.10 (0.23-3.22) | 5.88 (1.70-20.3) |
| No MMF | 251 | 15 (6.0) | 79 910 | 0.19 (0.11-0.31) | — |
| T-cell manipulation | 49 | 3 (6.1) | 16 245 | 0.18 (0.04-0.54) | 0.82 (0.24-2.82) |
| No T-cell manipulation | 215 | 15 (7.0) | 66 384 | 0.23 (0.13-0.37) | — |
| Corticosteroids | 100 | 11 (11) | 29 578 | 0.37 (0.19-0.67) | 2.82 (1.09-7.27) |
| No corticosteroids | 164 | 7 (4.3) | 53 051 | 0.13 (0.05-0.27) | — |
| GVHD severity | |||||
| No and nonsevere GVHD | 211 | 8 (3.8) | 69 881 | 0.11 (0.05-0.23) | 6.85 (2.70-17.4) |
| Severe GVHD | 53 | 10 (18.9) | 12 748 | 0.78 (0.38-1.44) | — |
Characteristic . | No. . | IFI (%)* . | Days after HSCT . | IR (95% CI)† . | IRR (95% CI)‡ . |
|---|---|---|---|---|---|
| Cohort | 264 | 18 (6.8) | 82 629 | 0.22 (0.13-0.34) | — |
| Sex | |||||
| Female | 107 | 7 (6.5) | 34 346 | 0.20 (0.11-0.41) | — |
| Male | 157 | 11 (7.0) | 48 283 | 0.23 (0.08-0.42) | 1.12 (0.43-2.88) |
| Age, y | |||||
| 18-44 | 135 | 6 (4.4) | 46 861 | 0.13 (0.05-0.28) | — |
| 45-66 | 129 | 12 (9.3) | 35 768 | 0.34 (0.17-0.59) | 2.62 (0.98-6.98) |
| Transplant type | |||||
| Myeloablative | 197 | 8 (4.1) | 64 642 | 0.12 (0.05-0.24) | — |
| Nonmyeloablative | 67 | 10 (14.9) | 17 987 | 0.56 (0.27-1.02) | 4.49 (1.77-11.4) |
| Relationship to donor | |||||
| Related | 143 | 3 (2.1) | 47 156 | 0.06 (0.01-0.19) | — |
| Unrelated | 121 | 15 (12.4) | 35 473 | 0.42 (0.24-0.70) | 6.65 (1.92-23.0) |
| Stem cell source | |||||
| Bone marrow | 164 | 9 (5.5) | 57 717 | 0.16 (0.07-0.30) | — |
| Peripheral blood | 100 | 9 (9) | 24 912 | 0.36 (0.17-0.69) | 2.32 (0.92-5.84) |
| Risk group | |||||
| Low risk | 80 | 3 (3.8) | 30 824 | 0.10 (0.02-0.28) | — |
| High risk | 184 | 15 (8.2) | 51 805 | 0.29 (0.16-0.48) | 2.98 (0.86-10.3) |
| CMV serology of donor/recipient | |||||
| Any seropositive | 137 | 10 (7.3) | 41 868 | 0.24 (0.12-0.44) | 1.30 (0.50-3.42) |
| D-/R- | 118 | 7 (5.9) | 38 105 | 0.18 (0.07-0.38) | — |
| GVHD prophylaxis | |||||
| Methotrexate | 142 | 5 (3.5) | 43 886 | 0.11 (0.04-0.27) | 0.34 (0.12-0.95) |
| No methotrexate | 122 | 13 (10.7) | 38 743 | 0.34 (0.18-0.57) | — |
| Cyclosporine | 121 | 13 (10.7) | 41 729 | 0.31 (0.17-0.53) | 2.55 (0.91-7.15) |
| No cyclosporine | 143 | 5 (3.5) | 40 900 | 0.12 (0.04-0.29) | — |
| Tacrolimus | 107 | 2 (1.9) | 27 257 | 0.07 (0.01-0.27) | 0.25 (0.06-1.10) |
| No tacrolimus | 157 | 16 (10.2) | 55 372 | 0.29 (0.17-0.47) | — |
| Sirolimus | 43 | 1 (2.3) | 11 492 | 0.09 (0.00-0.49) | 0.36 (0.05-2.74) |
| No sirolimus | 221 | 17 (7.7) | 71 137 | 0.24 (0.14-0.38) | — |
| MMF | 13 | 3 (23.1) | 2 719 | 1.10 (0.23-3.22) | 5.88 (1.70-20.3) |
| No MMF | 251 | 15 (6.0) | 79 910 | 0.19 (0.11-0.31) | — |
| T-cell manipulation | 49 | 3 (6.1) | 16 245 | 0.18 (0.04-0.54) | 0.82 (0.24-2.82) |
| No T-cell manipulation | 215 | 15 (7.0) | 66 384 | 0.23 (0.13-0.37) | — |
| Corticosteroids | 100 | 11 (11) | 29 578 | 0.37 (0.19-0.67) | 2.82 (1.09-7.27) |
| No corticosteroids | 164 | 7 (4.3) | 53 051 | 0.13 (0.05-0.27) | — |
| GVHD severity | |||||
| No and nonsevere GVHD | 211 | 8 (3.8) | 69 881 | 0.11 (0.05-0.23) | 6.85 (2.70-17.4) |
| Severe GVHD | 53 | 10 (18.9) | 12 748 | 0.78 (0.38-1.44) | — |
— indicates reciprocal rate not shown for clarity.
Percent indicates incidence proportion, independent of person-time at risk contributed.
Cases/1000 patient-days of observation from HSCT date (day 0). Confidence intervals were calculated using the Haenszel method.
IRR indicates crude incidence rate ratio, when compared to complementary characteristic in the preceding row. Confidence intervals were calculated using the Byar method.